{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:39:24Z","timestamp":1793165964946,"version":"4.5.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oral. Health"],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Medication-related osteonecrosis of the Jaw (MRONJ) is an adverse drug reaction that affects the mandible and maxilla of patients exposed to BMA and AA therapies, causing the progressive destruction and death of bone. To date, oral health preventive measures remain the most effective strategy to reduce MRONJ incidence, and, in this sense, the major goal is to diagnose, treat, and eradicate any oral diseases that could compromise oral health. The present systematic review aims to investigate the awareness of MRONJ among patients assuming BMAs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was performed, selecting studies that concern the awareness of patients of the risk of MRONJ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Six studies were included in this review. In total, 483 patients were evaluated. Of the 483 included patients, 391 were not aware of the possibility of MRONJ onset (391\/483, 81%) and 92 were aware of it (92\/483, 19%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The problem of patient's lack of awareness with respect to MRONJ risk presents different layers of complexity (\u201cwhat?\u201d, \u201cwho?\u201d, \u201cwhere?\u201d, \u201cwhen?\u201d and \u201cwhy?\u201d). Among its causal factors, there are an inadequate level of communication with patients and the lack of collaboration between healthcare professionals, which is related to an individualistic view of liability and deontological duties. MRONJ is a drug adverse reaction that can greatly affect the quality of life of patients if not promptly diagnosed and treated. Therefore, patients must be fully aware of the risks of adverse and the importance of preventive measures, which imply effective and exhaustive communication by each member of the multidisciplinary team. Effective teamwork and collaborative care should be promoted to positively impact patients' awareness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/froh.2024.1441601","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T01:11:25Z","timestamp":1722474685000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":15,"title":["Drug assumption and awareness about adverse drug reactions. The right to know. The case of the bone-modyfing agents: a systematic review"],"prefix":"10.3389","volume":"5","author":[{"given":"Rodolfo","family":"Mauceri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Arduini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Coppini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Bazzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Trujillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/odi.14887","article-title":"Italian Position paper (SIPMO-SICMF) on medication-related osteonecrosis of the jaw (MRONJ)","author":"Bedogni","year":"2024","journal-title":"Oral Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"106689","DOI":"10.1016\/j.oraloncology.2024.106689","article-title":"Challenges in the diagnosis of oral squamous cell carcinoma mimicking medication-related osteonecrosis of the jaws: a multi-hospital-based case series","volume":"151","author":"Mauceri","year":"2024","journal-title":"Oral Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.1007\/s00520-022-06982-y","article-title":"One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ)","volume":"30","author":"Fusco","year":"2022","journal-title":"Support Care Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"196","DOI":"10.36401\/JIPO-21-14","article-title":"Medication-related osteonecrosis of the jaw in patients treated concurrently with antiresorptive and antiangiogenic agents: systematic review and meta-analysis","volume":"4","author":"Srivastava","year":"2021","journal-title":"J Immunother Precis Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s40729-021-00323-0","article-title":"Clinical considerations for medication-related osteonecrosis of the jaw: a comprehensive literature review","volume":"7","author":"Kawahara","year":"2021","journal-title":"Int J Implant Dent"},{"key":"B6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12903-023-02732-6","article-title":"MRONJ In breast cancer patients under bone modifying agents for cancer treatment-induced bone loss (CTIBL): a multi-hospital-based case series","volume":"23","author":"Mauceri","year":"2023","journal-title":"BMC Oral Health"},{"key":"B7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.ejca.2017.01.028","article-title":"Denosumab in advanced\/unresectable giant-cell tumour of bone (GCTB): for how long?","volume":"76","author":"Palmerini","year":"2017","journal-title":"Eur J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1007\/s00520-022-06839-4","article-title":"Prognosis by cancer type and incidence of zoledronic acid-related osteonecrosis of the jaw: a single-center retrospective study","volume":"30","author":"Hata","year":"2022","journal-title":"Support Care Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1470-2045(18)30862-3","article-title":"Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Gnant","year":"2019","journal-title":"Lancet Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s00784-013-1012-5","article-title":"Prevalence of bisphosphonate-associated osteonecrosis of the jaw after intravenous zoledronate infusions in patients with early breast cancer","volume":"18","author":"Rugani","year":"2014","journal-title":"Clin Oral Investig"},{"key":"B13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.oooo.2018.02.003","article-title":"Medication-related osteonecrosis of the jaw: an update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention","volume":"125","author":"Owosho","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br Med J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.14219\/jada.archive.2010.0229","article-title":"How patients\u2019 lack of knowledge about oral bisphosphonates can interfere with medical and dental care","volume":"141","author":"Migliorati","year":"2010","journal-title":"J Am Dent Assoc"},{"key":"B17","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jcms.2011.04.011","article-title":"Awareness and education of patients receiving bisphosphonates","volume":"40","author":"Bauer","year":"2012","journal-title":"J Craniomaxillofac Surg"},{"key":"B18","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.jsps.2020.05.004","article-title":"Awareness among patient at risk of developing medication related osteonecrosis of the jaw (MRONJ)? A primary prevention strategy","volume":"28","author":"Al Abdullateef","year":"2020","journal-title":"Saudi Pharm J"},{"key":"B19","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/0300060520955066","article-title":"Awareness of the risk of developing medication-related osteonecrosis of the jaw among bisphosphonate users","volume":"48","author":"El-Ma\u2019aita","year":"2020","journal-title":"J Int Med Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.5195\/D3000.2022.362","article-title":"Patients\u2019 awareness of the complications of bisphosphonate therapy","volume":"10","author":"Hristamyan","year":"2022","journal-title":"Dent 3000"},{"key":"B21","doi-asserted-by":"publisher","first-page":"C7","DOI":"10.1590\/1807-3107BOR-2022.VOL36.0126","article-title":"Awareness of patients receiving bisphosphonates: a cross-sectional study","volume":"36","author":"De Lima-Souza","year":"2022","journal-title":"Braz Oral Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00774-013-0489-y","article-title":"Bisphosphonate-related osteonecrosis of the jaws: legal liability from the perspective of the prescribing physician","volume":"31","author":"Lo Russo","year":"2013","journal-title":"J Bone Miner Metab"},{"key":"B23","first-page":"3","article-title":"The nature of consent","volume-title":"The Ethics of Consent: Theory and Practice","author":"Kleinig","year":"2010"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4019","DOI":"10.1007\/s00520-020-05440-x","article-title":"Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals","volume":"28","author":"Drudge-Coates","year":"2020","journal-title":"Support Care Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2684924","DOI":"10.1155\/2018\/2684924","article-title":"The dental management of patients at risk of medication-related osteonecrosis of the jaw: new paradigm of primary prevention","volume":"2018","author":"Di Fede","year":"2018","journal-title":"Biomed Res Int"},{"key":"B26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1177\/0969733012468466","article-title":"The ethics of interprofessional collaboration","volume":"20","author":"Engel","year":"2013","journal-title":"Nurs Ethics"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.1007\/s00520-022-06940-8","article-title":"The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists","volume":"30","author":"Mauceri","year":"2022","journal-title":"Support Care Cancer"},{"key":"B28","volume-title":"Raccomandazioni clinico-terapeutiche sull'osteonecrosi delle ossa mascellari (ONJ) farmaco-relata e sua prevenzione","author":"Campisi","year":""},{"key":"B29","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1080\/13561820500082529","article-title":"The conceptual basis for interprofessional collaboration: core concepts and theoretical frameworks","volume":"19","author":"D'Amour","year":"2005","journal-title":"J Interprof Care"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1009080","DOI":"10.3389\/fpsyg.2022.1009080","article-title":"Diagnostic delay of oral squamous cell carcinoma and the fear of diagnosis: a scoping review","volume":"13","author":"Mauceri","year":"2022","journal-title":"Front Psychol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"15579883211016361","DOI":"10.1177\/15579883211016361","article-title":"Men and oral health: a review of sex and gender differences","volume":"15","author":"Lipsky","year":"2021","journal-title":"Am J Mens Health"},{"key":"B32","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11019-017-9789-7","article-title":"Relational autonomy in informed consent (RAIC) as an ethics of care approach to the concept of informed consent","volume":"21","author":"Osuji","year":"2018","journal-title":"Med Health Care Philos"},{"key":"B33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/13561820220146685","article-title":"Commitment to health: a shared ethical bond between professions","volume":"16","author":"Seedhouse","year":"2002","journal-title":"J Interprof Care"},{"key":"B34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3109\/13561820.2011.645958","article-title":"Collaborative care best practice models: a new educational paradigm for developing interprofessional educational (IPE) experiences","volume":"26","author":"Owen","year":"2012","journal-title":"J Interprof Care"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/su142013157","article-title":"Current trends in interprofessional shared decision-making programmes in health professions education: a scoping review","volume":"14","author":"Sultan","year":"2022","journal-title":"Sustainability"}],"container-title":["Frontiers in Oral Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2024.1441601\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T01:11:28Z","timestamp":1722474688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/froh.2024.1441601\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,1]]},"references-count":35,"alternative-id":["10.3389\/froh.2024.1441601"],"URL":"https:\/\/doi.org\/10.3389\/froh.2024.1441601","relation":{},"ISSN":["2673-4842"],"issn-type":[{"value":"2673-4842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,1]]},"article-number":"1441601"}}